Open an account

Ultragenyx Pharmaceutical

RARE · NASDAQ

$16.02+$0.95 (+6.30%)TodayMarket closed ·
Prev close $15.07

About RARE

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. The company is headquartered in Novato, California and currently employs 1,371 full-time employees. The company went IPO on 2014-01-31. The firm is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.

Employees
1,371
Headquarters
Novato, California
Listed
Jan 31, 2014
Sector
Health Care
Industry
Biotechnology
Website
ultragenyx.com

RARE key statistics

Market cap
1.58B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
4.33M
Volume
3.55M
Open price
$15.08
High today
$16.27
Low today
$14.99
52 Week high
$39.89
52 Week low
$12.73

Ultragenyx Pharmaceutical (RARE) at a glance

As of Oct 20, 2026, Ultragenyx Pharmaceutical (RARE) shares are priced at $16.02, giving the company a market cap of 1.58B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $14.99 and $16.27. The current price is 6.9% above the day's low and 1.5% below its high.

Volume so far is 3.55M shares, in line with the average of 4.33M shares a day.

Over the past year Ultragenyx Pharmaceutical has ranged from $12.73 to $39.89, and now sits 12% of the way up that range.

Ultragenyx Pharmaceutical met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.90 per share against an estimate of -$1.24.

The average analyst price target is $26.69, 66.6% above the current price, from 23 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

65%of 23 analyst ratings say Buy
  • Buy65.2%
  • Hold34.8%
  • Sell0.0%
Price target · 21 analystsAvg $26.69
Low
$16.16
Now
$16.02
High
$40.95

RARE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 12.3% on average.

  1. Q3 FY24: reported -$1.40 per share against an estimate of -$1.48
  2. Q4 FY24: reported -$1.39 per share against an estimate of -$1.32
  3. Q1 FY25: reported -$1.57 per share against an estimate of -$1.65
  4. Q2 FY25: reported -$1.17 per share against an estimate of -$1.32
  5. Q3 FY25: reported -$1.81 per share against an estimate of -$1.26
  6. Q4 FY25: reported -$1.29 per share against an estimate of -$1.11
  7. Q1 FY26: reported -$1.84 per share against an estimate of -$1.54
  8. Q2 FY26: reported -$0.90 per share against an estimate of -$1.24

RARE news

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

  • Vandana Singh

    Ultragenyx Wins First Sanfilippo Approval As Analyst Keeps Ratings Modest

  • Mohd Haider

    Ultragenyx Pharmaceutical (RARE) Stock Jumps After Hours: Here's Why It Is Trending

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

  • Erica Kollmann

    QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target

  • Avi Kapoor

    Gold Jumps 3%; ISM Services PMI Rises In August

Similar companies

Companies in the same industry as Ultragenyx Pharmaceutical

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.